Evidence map›Paper›PMID 21289249›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2011

Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults.

N Binkley, D Gemar, J Engelke, R Gangnon, R Ramamurthy, D Krueger, M K Drezner

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 7 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 7 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Vitamin D supplementation for prevention of mortality in adults.The Cochrane database of systematic reviews · 2014
    Pooled it
  7. Pooled it
  8. Trial
  9. Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Trial
  10. The Effect of Bolus Vitamin DJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

N BinkleyOsteoporosis Clinical Center and Research Program,University of Wisconsin, Madison, Wisconsin 53705, USA. nbinkley@wisc.edu
D Gemar
J Engelke
R Gangnon
R Ramamurthy
D Krueger
M K Drezner
University of Wisconsin–Madison · US

Funding

PATHOGENESIS OF VITAMIN D REFRACTORY DISEASESR01AR027032 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 1986 to 2015
$3.5M
NIAMS NIH HHS R01 AR027032
6 · The paper itself

Abstract

contextWhether ergocalciferol (D(2)) and cholecalciferol (D(3)) are equally effective to increase and maintain serum 25-hydroxyvitamin D [25(OH)D] concentration is controversial.

objectiveThe aim of the study was to evaluate the effect of daily and once monthly dosing of D(2) or D(3) on circulating 25(OH)D and serum and urinary calcium. DESIGN, SETTING AND

participantsIn a university clinical research setting, 64 community dwelling adults age 65+ were randomly assigned to receive daily (1,600 IU) or once-monthly (50,000 IU) D(2) or D(3) for 1 yr.

main outcome measuresSerum 25(OH)D, serum calcium, and 24-h urinary calcium were measured at months 0, 1, 2, 3, 6, 9, and 12. Serum PTH, bone-specific alkaline phosphatase, and N-telopeptide were measured at months 0, 3, 6, and 12.

resultsSerum 25(OH)D was less than 30 ng/ml in 40% of subjects at baseline; after 12 months of vitamin D dosing, levels in 19% of subjects (n = 12, seven receiving daily doses and five monthly doses) remained low, despite compliance of more than 91%. D(2) dosing increased 25(OH)D(2) but produced a decline (P < 0.0001) in 25(OH)D(3). Substantial between-individual variation in 25(OH)D response was observed for both D(2) and D(3). The highest 25(OH)D observed was 72.5 ng/ml. Vitamin D administration did not alter serum calcium, PTH, bone-specific alkaline phosphatase, N-telopeptide, or 24-h urine calcium.

conclusionsOverall, D(3) is slightly, but significantly, more effective than D(2) to increase serum 25(OH)D. One year of D(2) or D(3) dosing (1,600 IU daily or 50,000 IU monthly) does not produce toxicity, and 25(OH)D levels of less than 30 ng/ml persist in approximately 20% of individuals. Substantial between-individual response to administered vitamin D(2) or D(3) is observed.

Indexed as

AgedAged, 80 and overBone Density Conservation AgentsCalciumCholecalciferolCircadian RhythmDosage FormsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleErgocalciferolsFemaleHumansMaleOsteoporosisPlacebosBone Density Conservation AgentsCalciumCholecalciferolDosage FormsErgocalciferolsPlacebosVitamin D

Identifiers

PMID21289249
PMCPMC3417158
OpenAlexW1993714787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.